Evidence map›Paper›PMID 42022881›Full record

ArticleSmall science2026

Evaluation of Tetraspanins in Extracellular Vesicle Bioengineering.

Doste R Mamand, Oskar Gustafsson, Helena Sork, Rim Jawad Wiklander, Safa Bazaz, Xiuming Liang, Vicky W Q Hou, Taavi Lehto, Dhanu Gupta, André Görgens and 3 more

Abstract read
In one paragraph

Article in Small science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Doste R MamandDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.ORCID https://orcid.org/0000-0002-4785-0796
Oskar GustafssonDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
Helena SorkInstitute of Technology University of Tartu Tartu Estonia.
Rim Jawad WiklanderDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
Safa BazazCenter for Hematology and Regenerative Medicine (HERM) Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden.
Xiuming LiangDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
Vicky W Q HouDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
Taavi LehtoDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
Dhanu GuptaDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
André GörgensDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
Joel Z NordinDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.
Samir E L AndaloussiDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.ORCID https://orcid.org/0000-0003-4468-9113
Oscar P B WiklanderDepartment of Laboratory Medicine Division of Biomolecular and Cellular Medicine Karolinska Institute Stockholm Sweden.ORCID https://orcid.org/0000-0003-1176-8114

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are nano-scale structures produced by cells that transport biological substances for intercellular communication. The tetraspanins CD9, CD81, and CD63 are crucial to EV biogenesis and function. This study uses CRISPR-Cas9 system to knock out (KO) CD9, CD63, and CD81 in HEK293T cells. The goal is to investigate the role of these tetraspanins in EV bioengineering with the hypothesis that repressing endogenous production may increase the availability of exogenously introduced tetraspanin-fusion constructs and increase engineered EV production. First, it is observed that individually knocking out a tetraspanin does not significantly affect EV formation. However, when all three tetraspanins are simultaneously knocked out, there is a marked decrease in EV production, as measured by nanoparticle tracking analysis. Second, upon reintroduction of the corresponding tetraspanins fused to firefly ThermoLuc or neon green into the PanKO-, CD9KO-, CD63KO-, and CD81KO-cells, the engineered EVs display a significant increase in production by 50% to 70% compared to transduction of wild-type cells, as measured by luminometer and imaging flow cytometry. These findings emphasize the potential of tetraspanin KO in the bioengineering of EVs, paving the way for new therapeutic applications by enhancing production and potentially modifying their cargo.

Indexed as

CD63CD81CD9CRISPR‐Cas9EV releaseEVs bioengineeringtetraspanins

Identifiers

PMID42022881
PMCPMC13098096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.